Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know

Impact · against what's priced in

The article provides a bullish outlook for Immunome based on analyst price targets and earnings revisions, but these are trailing indicators rather than new catalysts. Because there is no evidence of a fundamental shift in the company's asset pipeline or revenue streams, the impact remains modest.

IMNM+0.20

No priced-in read yet